1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Tempest Delivers A Thunderbolt

 
• By Elizabeth Cairns

Slam-dunk mid-stage data in liver cancer send TPST-1120 towards a pivotal trial, though Tempest will need both cash and a partner to fulfil the PPAR⍺ antagonist’s potential.  

Lightning-strike

Addition of the PPAR⍺ antagonist TPST-1120 to standard of care in hepatocellular carcinoma (HCC) boosted survival in an ongoing Phase I/IIb study, Tempest Therapeutics, Inc. said on 11 October. The readout catapulted Tempest out of penny stock territory, its closing price of $9.77 on the NASDAQ representing an astonishing one-day increase of 3,971%.

Key Takeaways
  • Roche’s Morpheus-Liver trial backs Tempest’s PPAR⍺ antagonist in first-line hepatocellular carcinoma

The product is now ready for the pivotal stage – but with an approval trial likely to cost around $100m,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 
• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.